Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

被引：72

作者：

Younossi, Zobair M. ^{[1
,2
]}

Henry, Linda ^{[1
,2
,3
]}

机构：

[1] Inova Fairfax Hosp, Dept Med, Falls Church, VA 22042 USA

[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[3] Ctr Outcomes Res Liver Dis, Washington, DC USA

来源：

PHARMACOECONOMICS | 2015年 / 33卷 / 12期

关键词：

WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; CLINICAL EFFECTIVENESS; COST-EFFECTIVENESS; BARIATRIC SURGERY; CARE MODEL; OBESITY; NAFLD; STEATOHEPATITIS; POPULATION;

D O I：

10.1007/s40273-015-0316-5

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a very common chronic liver disease worldwide, is on the rise following the trend of increasing prevalence of obesity, is the second most common indication for liver transplantation, and is an important cause for hepatocellular carcinoma. Despite the increasing recognition of NAFLD as an important chronic liver disease, little has been published on the economic and health-related quality of life (HR-QOL) impact of NAFLD. We reviewed the current literature related to the economics and HR-QOL of NAFLD and found that increased costs and decreased HR-QOL were associated with NAFLD.

引用

页码：1245 / 1253

页数：9

共 45 条

[1] Predictors of health-related quality of life in patients with chronic liver disease [J].

Afendy, A. ;

Kallman, J. B. ;

Stepanova, M. ;

Younoszai, Z. ;

Aquino, R. D. ;

Bianchi, G. ;

Marchesini, G. ;

Younossi, Z. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (05) :469-476

[2]

[Anonymous], HEPAT MON

[3] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis [J].

Anstee, Quentin M. ;

Targher, Giovanni ;

Day, Christopher P. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) :330-344

[4] Non-alcoholic steatohepatitis: Effect of Roux-en-Y gastric bypass surgery [J].

Barker, KB ;

Palekar, NA ;

Bowers, SP ;

Goldberg, JE ;

Pulcini, JP ;

Harrison, SA .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (02) :368-373

[5] Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease [J].

Barshop, N. J. ;

Sirlin, C. B. ;

Schwimmer, J. B. ;

Lavine, J. E. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) :13-24

[6] Impact of fatty liver disease on health care utilization and costs in a general population:: A 5-year observation [J].

Baumeister, Sebastian E. ;

Voelzke, Henry ;

Marschall, Paul ;

John, Ulrich ;

Schmidt, Carsten-Oliver ;

Flessa, Steffen ;

Alte, Dietrich .

GASTROENTEROLOGY, 2008, 134 (01) :85-94

[7] Nonalcoholic fatty liver disease and aging: Epidemiology to management [J].

Bertolotti, Marco ;

Lonardo, Amedeo ;

Mussi, Chiara ;

Baldelli, Enrica ;

Pellegrini, Elisa ;

Ballestri, Stefano ;

Romagnoli, Dante ;

Loria, Paola .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (39) :14185-14204

[8] Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings [J].

Brunt, Elizabeth M. ;

Kleiner, David E. ;

Wilson, Laura A. ;

Belt, Patricia ;

Neuschwander-Tetri, Brent A. .

HEPATOLOGY, 2011, 53 (03) :810-820

[9] The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Diehl, Anna Mae ;

Brunt, Elizabeth M. ;

Cusi, Kenneth ;

Charlton, Michael ;

Sanyal, Arun J. .

HEPATOLOGY, 2012, 55 (06) :2005-2023

[10] Health-related quality of life in patients with non-alcoholic fatty liver disease [J].

Dan, A. A. ;

Kallman, J. B. ;

Wheeler, A. ;

Younoszai, Z. ;

Collantes, R. ;

Bondini, S. ;

Gerber, L. ;

Younossi, Z. M. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (06) :815-820

← 1 2 3 4 5 →